151 related articles for article (PubMed ID: 36945825)
1. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
Taipale H; Tanskanen A; Tiihonen J
Am J Psychiatry; 2023 May; 180(5):377-385. PubMed ID: 36945825
[TBL] [Abstract][Full Text] [Related]
2. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
4. Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.
Sommer IE; Brand BA; Gangadin S; Tanskanen A; Tiihonen J; Taipale H
Schizophr Bull; 2023 Jan; 49(1):136-143. PubMed ID: 36198044
[TBL] [Abstract][Full Text] [Related]
5. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.
Taipale H; Tanskanen A; Luykx JJ; Solmi M; Leucht S; Correll CU; Tiihonen J
Schizophr Bull; 2022 Jun; 48(4):774-784. PubMed ID: 35524479
[TBL] [Abstract][Full Text] [Related]
6. Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders.
Korkmaz ŞA; Koca E; Yilmaz Ö; Özbek T; Güçlü MA; Kizgin S
J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):250-257. PubMed ID: 38489589
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study.
Joo SW; Kim H; Jo YT; Ahn S; Choi YJ; Choi W; Park S; Lee J
Eur Neuropsychopharmacol; 2022 Jun; 59():36-44. PubMed ID: 35550204
[TBL] [Abstract][Full Text] [Related]
8. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.
Taipale H; Tanskanen A; Correll CU; Tiihonen J
Lancet Psychiatry; 2022 Apr; 9(4):271-279. PubMed ID: 35182475
[TBL] [Abstract][Full Text] [Related]
11. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
12. Description of long-term polypharmacy among schizophrenia outpatients.
Suokas JT; Suvisaari JM; Haukka J; Korhonen P; Tiihonen J
Soc Psychiatry Psychiatr Epidemiol; 2013 Apr; 48(4):631-8. PubMed ID: 23007295
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
Essock SM; Schooler NR; Stroup TS; McEvoy JP; Rojas I; Jackson C; Covell NH;
Am J Psychiatry; 2011 Jul; 168(7):702-8. PubMed ID: 21536693
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.
Correll CU; Rummel-Kluge C; Corves C; Kane JM; Leucht S
Schizophr Bull; 2009 Mar; 35(2):443-57. PubMed ID: 18417466
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.
Fisher MD; Reilly K; Isenberg K; Villa KF
BMC Psychiatry; 2014 Nov; 14():341. PubMed ID: 25433495
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
18. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease.
Koponen M; Taipale H; Lavikainen P; Tanskanen A; Tiihonen J; Tolppanen AM; Ahonen R; Hartikainen S
J Alzheimers Dis; 2017; 56(1):107-118. PubMed ID: 27935554
[TBL] [Abstract][Full Text] [Related]
19. QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy.
Elliott A; Mørk TJ; Højlund M; Christensen T; Jeppesen R; Madsen N; Viuff AG; Hjorth P; Nielsen JC; Munk-Jørgensen P
CNS Spectr; 2018 Aug; 23(4):278-283. PubMed ID: 28659221
[TBL] [Abstract][Full Text] [Related]
20. Subjective Medication Satisfaction With Antipsychotic Polypharmacy in a Naturalistic Inpatient and Outpatient Sample.
Kikkert MJ; de Mooij L; de Koning M; Dekker J
J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
